Viking Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 7, 2024
VKTX$28.99+8.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Operations and Comprehensive Loss
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues | $— | $— | $— |
| Operating expenses: | |||
| Research and development | 63,806 | 54,234 | 44,981 |
| General and administrative | 37,021 | 16,121 | 10,701 |
| Total operating expenses | 100,827 | 70,355 | 55,682 |
| Loss from operations | (100,827) | (70,355) | (55,682) |
| Other income (expense): | |||
| Amortization of financing costs | (88) | (59) | (18) |
| Interest income, net | 15,020 | 1,589 | 703 |
| Realized loss on investments, net | — | (42) | — |
| Foreign exchange gain | — | — | 7 |
| Total other income, net | 14,932 | 1,488 | 692 |
| Net loss | (85,895) | (68,867) | (54,990) |
| Other comprehensive loss, net of tax: | |||
| Unrealized gain (loss) on securities | 742 | (295) | (495) |
| Foreign currency translation loss | (29) | (258) | — |
| Comprehensive loss | $(85,182) | $(69,420) | $(55,485) |
| Basic and diluted net loss per share | $(0.91) | $(0.90) | $(0.71) |
| Weighted-average shares used to compute basic and diluted net loss per share | 94,347 | 76,834 | 77,198 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.